Max Healthcare Institute Limited is a big player in healthcare. They do a lot of things like running clinics, hospitals, and specialized medical services. Healthcare is super important in India and worldwide. In India, with so many people and diverse health needs, good healthcare is crucial. Globally, the healthcare industry helps tackle health issues everywhere. Max Healthcare is in a good spot to grow because of its role in this important sector.
Max Healthcare’s key role in the growing healthcare industry, it might have a good chance of growing and reaching higher stock prices. It’s like saying Max Healthcare could be a strong player in the stock market game. However, remember, predicting these things is never guaranteed, and it’s crucial to keep an eye on how the company is doing in the market.
About Max Healthcare
Recent News Around Max Healthcare
Max Healthcare Q2 Fy2024 Key Points And Summary:
Max Healthcare Share Price Target 2024 To 2030
Max Healthcare Share Price Target 2024
When | Maximum Price | Minimum Price |
January 2024 | ₹838.16 | ₹728.83 |
February 2024 | ₹855.26 | ₹743.71 |
March 2024 | ₹872.72 | ₹758.89 |
April 2024 | ₹847.30 | ₹736.78 |
May 2024 | ₹834.78 | ₹725.89 |
June 2024 | ₹864.83 | ₹752.03 |
July 2024 | ₹856.18 | ₹744.51 |
August 2024 | ₹890.43 | ₹774.29 |
September 2024 | ₹926.05 | ₹805.26 |
October 2024 | ₹907.89 | ₹789.47 |
November 2024 | ₹935.13 | ₹813.15 |
December 2024 | ₹958.50 | ₹833.48 |
The projected share price targets for Max Healthcare in 2024 reveal critical points that investors should consider. The minimum and maximum prices for each month indicate potential fluctuations. Notably, December 2024 shows a significant expected price range with a maximum of ₹958.50 and a minimum of ₹833.48. This suggests a considerable potential upside for investors.
Investors should note the positive momentum backed by sound fundamentals, making the stock potentially lucrative in the coming year. However, as with any investment, it’s crucial to monitor market dynamics and external factors that may influence the expected price movement.
Max Healthcare Share Price Target 2025
when | Maximum Price | Minimum Price |
January 2025 | ₹977.67 | ₹752.06 |
February 2025 | ₹1,002.74 | ₹771.34 |
March 2025 | ₹1,041.85 | ₹801.42 |
April 2025 | ₹1,021.42 | ₹785.71 |
May 2025 | ₹991.67 | ₹762.82 |
June 2025 | ₹1,036.30 | ₹797.15 |
July 2025 | ₹1,015.98 | ₹781.52 |
August 2025 | ₹1,047.40 | ₹805.69 |
September 2025 | ₹1,084.06 | ₹833.89 |
October 2025 | ₹1,112.24 | ₹855.57 |
November 2025 | ₹1,140.05 | ₹876.96 |
December 2025 | ₹1,168.55 | ₹898.88 |
In 2025, Max Healthcare’s share price targets reveal a consistent upward trajectory, signaling favorable prospects for potential investors. The monthly projections consistently indicate growth, with both minimum and maximum prices on an ascending trend throughout the year. Notably, December 2025 stands out as a month with a projected peak, reaching a maximum of ₹1,168.55.
This optimistic outlook may be influenced by robust financial performance, strategic initiatives, or positive market conditions. Investors should closely scrutinize these critical points, acknowledging the sustained growth pattern and the potential for a significant year-end surge.
Max Healthcare Share Price Target 2026 To 2030
Year | Maximum Price (₹) | Minimum Price (₹) |
---|---|---|
2026 | ₹1,226.98 | ₹858.88 |
2027 | ₹1,349.67 | ₹944.77 |
2028 | ₹1,889.54 | ₹944.77 |
2029 | ₹1,635.97 | ₹817.98 |
2030 | ₹2,126.76 | ₹1,488.73 |
Max Healthcare ‘s Financial Condition (Last 5 Years)
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
Sales + | 1,691 | 1,059 | 2,508 | 3,937 | 4,563 | 5,198 |
Expenses + | 1,535 | 965 | 2,101 | 2,986 | 3,322 | 3,747 |
Operating Profit | 156 | 94 | 407 | 951 | 1,241 | 1,451 |
OPM % | 9.00% | 9.00% | 16.00% | 24% | 27% | 28% |
Other Income + | 56 | 48 | -122 | 110 | 139 | 173 |
Interest | 101 | 83 | 179 | 101 | 84 | 59 |
Depreciation | 103 | 46 | 174 | 221 | 232 | 235 |
Profit before tax | 8 | 13 | -69 | 739 | 1,064 | 1,330 |
Tax % | 102% | -1% | -67% | 18% | -4% | |
Net Profit + | 0 | 59 | -138 | 605 | 1,104 | 1,057 |
EPS in Rs | -0.06 | 1.1 | -1.42 | 6.24 | 11.37 | 10.88 |
Dividend Payout % | 0% | 0% | 0% | 0% | 9% |
Over the past five years, Max Healthcare has exhibited a noteworthy financial performance, reflecting significant growth and resilience. From FY2019 to the trailing twelve months (TTM), the company’s sales have seen a remarkable surge, escalating from ₹1,691 crores to ₹5,198 crores. This impressive upward trajectory in revenue is coupled with a consistent increase in operating profit, reaching ₹1,451 crores with a robust operating profit margin of 28% in the TTM.
While the company faced a challenging period in FY2021 with negative earnings, it swiftly rebounded, reporting a substantial net profit of ₹1,057 crores in the TTM. Max Healthcare’s ability to recover from setbacks and achieve such a positive net profit underscores its adaptability and strategic management.
Moreover, the declining trend in tax percentage over the years, along with a consistent dividend payout of 9%, indicates the company’s effective tax management and commitment to returning value to shareholders. Despite facing fluctuations, Max Healthcare’s financial data suggests a resilient and promising outlook, making it an intriguing prospect for investors seeking stability and growth in the healthcare sector.
FAQS
Should one invest in Max Healthcare ?
Max Healthcare Institute Ltd, a prominent player in the healthcare sector, stands as India’s second-largest hospital chain, boasting significant leadership in terms of revenue, EBITDA, and market capitalization. As of February 2, 2024, the stock closed at ₹766, reflecting a 4.57% decrease.
The company demonstrates a robust financial position with a market capitalization of ₹74,483 Crores. It has maintained a stable book value of ₹80.7 and a face value of ₹10. Max Healthcare exhibits a Price-to-Earnings (P/E) ratio of 70.5, indicative of its growth prospects. On the positive side, Max Healthcare has strategically reduced its debt, resulting in almost debt-free status. The company has shown commendable profit growth, posting a 115% CAGR over the last 5 years. However, concerns arise as the stock trades at 9.49 times its book value, and there’s a notable decrease in promoter holding by 51.5% over the last 3 years. The return on equity (ROE) has been relatively low at 16.1%, prompting attention to operational efficiency.
Analyzing the quarterly results, Max Healthcare showcased consistent revenue growth, reaching ₹1,335 Crores in December 2023. The operating profit margin (OPM) improved to 29%, indicating operational efficiency. The net profit for the quarter was ₹289 Crores, demonstrating a positive trend.
Leave a Reply